KR20220149745A - 펩타이드를 이용한 염증성 질환의 치료 및 약학적 조성물 - Google Patents

펩타이드를 이용한 염증성 질환의 치료 및 약학적 조성물 Download PDF

Info

Publication number
KR20220149745A
KR20220149745A KR1020227034521A KR20227034521A KR20220149745A KR 20220149745 A KR20220149745 A KR 20220149745A KR 1020227034521 A KR1020227034521 A KR 1020227034521A KR 20227034521 A KR20227034521 A KR 20227034521A KR 20220149745 A KR20220149745 A KR 20220149745A
Authority
KR
South Korea
Prior art keywords
gly
compound
leu
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227034521A
Other languages
English (en)
Korean (ko)
Inventor
원상 유
래리 총 박
Original Assignee
주식회사 유유제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 유유제약 filed Critical 주식회사 유유제약
Publication of KR20220149745A publication Critical patent/KR20220149745A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020227034521A 2020-03-05 2021-03-05 펩타이드를 이용한 염증성 질환의 치료 및 약학적 조성물 Ceased KR20220149745A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985603P 2020-03-05 2020-03-05
US62/985,603 2020-03-05
PCT/IB2021/000423 WO2021191689A2 (en) 2020-03-05 2021-03-05 Treatment of inflammatory diseases with peptides and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
KR20220149745A true KR20220149745A (ko) 2022-11-08

Family

ID=77890982

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034521A Ceased KR20220149745A (ko) 2020-03-05 2021-03-05 펩타이드를 이용한 염증성 질환의 치료 및 약학적 조성물

Country Status (7)

Country Link
US (1) US20230146455A1 (enExample)
EP (1) EP4114430A4 (enExample)
JP (1) JP2023516677A (enExample)
KR (1) KR20220149745A (enExample)
CA (1) CA3170606A1 (enExample)
TW (1) TW202146426A (enExample)
WO (1) WO2021191689A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026049571A1 (ko) * 2024-08-29 2026-03-05 루다큐어 주식회사 통증 치료용 조성물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12037415B2 (en) 2017-05-17 2024-07-16 Yuyu Pharma, Inc. Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
US12575976B2 (en) 2021-11-08 2026-03-17 Recker Medical Urine quantifying bed pad
MX2024006997A (es) * 2021-12-13 2024-06-19 Eyebiokorea Inc Composicion para el tratamiento de la degeneracion macular que comprende un nuevo peptido.
WO2025149851A2 (en) * 2024-01-12 2025-07-17 Yuyu Pharma, Inc. Methods for treating inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
CA2711696C (en) * 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
ES2822289T3 (es) * 2016-04-08 2021-04-30 Eyebio Korea Péptido a base de colágeno tipo II alfa-1 para su uso en el tratamiento de la degeneración macular
KR101795653B1 (ko) * 2016-05-19 2017-11-09 인제대학교 산학협력단 콜라겐 타입 ii 펩타이드-아플리버셉트의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
KR20180074928A (ko) * 2016-12-26 2018-07-04 주식회사 아이바이오코리아 건성안 예방 또는 치료용 동물 의약품 조성물
US12037415B2 (en) * 2017-05-17 2024-07-16 Yuyu Pharma, Inc. Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient
TWI865470B (zh) * 2018-11-14 2024-12-11 南韓商柳柳製藥股份有限公司 治療眼睛疾病之肽及醫藥組合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026049571A1 (ko) * 2024-08-29 2026-03-05 루다큐어 주식회사 통증 치료용 조성물

Also Published As

Publication number Publication date
EP4114430A2 (en) 2023-01-11
WO2021191689A3 (en) 2021-12-23
EP4114430A4 (en) 2025-05-14
TW202146426A (zh) 2021-12-16
CA3170606A1 (en) 2021-09-30
WO2021191689A2 (en) 2021-09-30
US20230146455A1 (en) 2023-05-11
JP2023516677A (ja) 2023-04-20

Similar Documents

Publication Publication Date Title
EP4114430A2 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
JP7775250B2 (ja) 新規ペプチド及びその新規ペプチドを活性成分として含む眼疾患の治療のための医薬組成物
TWI865470B (zh) 治療眼睛疾病之肽及醫藥組合物
JP7601788B2 (ja) チロシンキナーゼの複素環式阻害剤
CN104606194A (zh) Pde4的双环杂芳基抑制剂
JP2021152056A (ja) 疾患を治療するためのｍｃｔ４阻害剤
US20220194940A1 (en) Heterocyclic inhibitors of tyrosine kinase
JP7834361B2 (ja) 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用
EP3253386B1 (en) Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same
CA3119921C (en) Peptides and pharmaceutical compositions for treating eye diseases
RU2819399C2 (ru) Пептиды и фармацевтические композиции для лечения глазных болезней
CN113072521B (zh) RORγt抑制剂及其在药物中的应用
HK40061089A (en) Peptides and pharmaceutical compositions for treating eye diseases
WO2025149851A2 (en) Methods for treating inflammatory diseases
HK40061089B (en) Peptides and pharmaceutical compositions for treating eye diseases
HK40017864A (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601